In a letter to the Medical Journal of Australia, a Monash
University-led team is asking for hepatitis C virus patients to gain
improved access to drugs to prevent liver related deaths.
Hepatitis C virus (HCV) infection is a major public health burden in
Australia, with estimates of 230,000 people chronically infected.
The research team are calling for the government to subsidize a new
therapy which has high cure rates, known as direct acting antiviral
Read more ...
Labels: access to new drugs, australia, Pharmaceutical Benefits Scheme (PBS)